

Carolina dos Santos¹; Catarina Castro¹; Maria Mergulhão¹; Ana Isabel Fernandes²

² Egas Moniz Center for Interdisciplinary Research (CiiEM); Egas Moniz School of Health & Science, Campus Universitário, Quinta da Granja, 2829-511 Caparica, Almada, Portugal

- Os **conjugados anticorpo-fármaco (ADC)** representam uma abordagem inovadora no tratamento do cancro, ao combinarem a **especificidade dos anticorpos monoclonais** com a **potência de agentes citotóxicos**, por **vetorização ativa**
- Permitem a **veiculação seletiva de fármacos citotóxicos diretamente às células tumorais**

- **Liga o anticorpo ao fármaco** e garante a **estabilidade e eficácia** do ADC

1. Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the "biological missile" for targeted cancer therapy. *Signal Transduct Target Ther* [Internet]. 2022 Dec 1 [cited 2025 May 19];7(1). Available from: <https://pubmed.ncbi.nlm.nih.gov/35318309/>
2. Lambert JM, Morris CQ. Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review. *Adv Ther* [Internet]. 2017 May 1 [cited 2025 May 19];34(5):1015–35. Available from: <https://pubmed.ncbi.nlm.nih.gov/28361465/>
3. Coats S, Williams M, Kebble B, Dixit R, Tseng L, Yano NS, et al. Antibody drug conjugates: Future directions in clinical and translational strategies to improve the therapeutic index. *Clinical Cancer Research [Internet]*. 2019 Sep 15 [cited 2025 May 19];25(18):5441–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/30979742/>
4. Sevilla-Carrillo I, García-Tercero E, Alonso-Moreno C, Moya-Lopez C. Antibody Drug Conjugates (ADCs): Shaping the Future of Precision Oncology. *Anticancer Agents Med Chem [Internet]*. 2025 Aug [cited 2025 May 19];25(14):993–1016. Available from: <https://pubmed.ncbi.nlm.nih.gov/39901681/>